(MedPage Today) — Treatment with setmelanotide (Imcivree), a melanocortin-4 receptor (MC4R) agonist, led to significant reductions in body mass index (BMI) and hunger in individuals with acquired hypothalamic obesity, the phase III TRANSCEND trial…
Source: MedPage Today — Headlines
